MedPath

Comparison of the effect of oral sotalol and oral metoprolol succinate in the prevention of atrial fibrillation after coronary artery bypass surgery.

Phase 3
Recruiting
Conditions
Condition 1: coronary artery bypass graft. Condition 2: Atrial fibrillation and flutter.
Atherosclerosis of coronary artery bypass graft(s) and coronary artery of transplanted heart with angina pectoris
Atrial fibrillation and flutter
I25.7
Registration Number
IRCT20231123060154N1
Lead Sponsor
Qazvin University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
188
Inclusion Criteria

Patients who are candidates for CABG

Exclusion Criteria

Previous history of atrial fibrillation
Having a permanent pacemaker
Any definite or probable evidence of having any type of ventricular or supraventricular arrhythmia
Moderate and severe LV enlargement
Moderate and severe valvular heart disease
acute MI
Prolonged QT
Patients with severe renal impairment and ESRD
Asthma and bronchospasm
Patients with hemodynamic disorders and low blood pressure
Patients who are taking drugs that interact with sotalol will be excluded from the study if it is not possible to stop the drug. These drugs include: All QT prolonging drugs including: Amiodarone, Amisulpride, Azithromycin, Carbetocin, Ceritinib, Chloroquine, Citalopram, Clarithromycin, Clofazimine, Clomipramine, Clozapine, Dabrafenib, Dasatinib, Domperidone, Doxepine-containing products, Droperidol, Encorafenib, Entrectinib ) otinib, Olanzapine, Ondansetron, Osimertinib, Oxytocin, Pacritinib, Pazopanib, Pentamidine, Pilsicainide, Pimozide, Piperaquine, Probucul, Propafenone, Propofol, Quetiapine, Ribociclib, risperidone, Sertindole, Sparfloxacin, Sunitinib, Terbutaline, Thioridazine, Toremifene, Vemurafenib : Alfuzocin, Alpha1- Blockers, Amifostine, Phenothiazines, Barbiturates, Benperidol, Levodpa- Containing products, Lormetazepam, Methoxyflurane, Molsidomine, Naftopidil, Nicergoline, Nicorandil, Nifedipine, Nitroprusside, Obinutuzumab, Pentoxyfilline, Pholcodine, Phosphodiesterase 5 inhibitors, Prostacyclin, Quinagolide, Reserpine: Acetylcholinesterase inhibitors, Ceritinib, Dipyridamole, Etilefrine, Ivabradine, Lacosamide, Midodrine, Ozanimod, Ponesimod, Siponimod, Blood sugar lowering drugs: Insulins, Sulfonylureas, Antidiabetic agents

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Occurrence of atrial fibrillation. Timepoint: Patients are continuously cardiac monitored for atrial fibrillation. Method of measurement: ECG.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath